rs35256489
Variant summary
Our verdict is Pathogenic. Variant got 14 ACMG points: 14P and 0B. PM1PM2PP3_ModeratePP5_Very_Strong
The NM_000518.5(HBB):c.332T>C(p.Leu111Pro) variant causes a missense change. The variant allele was found at a frequency of 0.0000131 in 152,212 control chromosomes in the GnomAD database, with no homozygous occurrence. In-silico tool predicts a pathogenic outcome for this variant. Variant has been reported in ClinVar as Pathogenic (★★). Synonymous variant affecting the same amino acid position (i.e. L111L) has been classified as Likely benign.
Frequency
Consequence
NM_000518.5 missense
Scores
Clinical Significance
Conservation
Genome browser will be placed here
ACMG classification
Verdict is Pathogenic. Variant got 14 ACMG points.
Transcripts
RefSeq
Gene | Transcript | HGVSc | HGVSp | Effect | #exon/exons | MANE | UniProt |
---|---|---|---|---|---|---|---|
HBB | NM_000518.5 | c.332T>C | p.Leu111Pro | missense_variant | 3/3 | ENST00000335295.4 |
Ensembl
Gene | Transcript | HGVSc | HGVSp | Effect | #exon/exons | TSL | MANE | Appris | UniProt |
---|---|---|---|---|---|---|---|---|---|
HBB | ENST00000335295.4 | c.332T>C | p.Leu111Pro | missense_variant | 3/3 | 1 | NM_000518.5 | P1 | |
HBB | ENST00000647020.1 | c.332T>C | p.Leu111Pro | missense_variant | 3/3 | P1 | |||
HBB | ENST00000475226.1 | n.264T>C | non_coding_transcript_exon_variant | 2/2 | 2 | ||||
HBB | ENST00000633227.1 | c.*148T>C | 3_prime_UTR_variant, NMD_transcript_variant | 3/3 | 3 |
Frequencies
GnomAD3 genomes ? AF: 0.0000131 AC: 2AN: 152212Hom.: 0 Cov.: 33
GnomAD3 exomes AF: 0.00000398 AC: 1AN: 251248Hom.: 0 AF XY: 0.00000736 AC XY: 1AN XY: 135792
GnomAD4 exome Cov.: 31
GnomAD4 genome ? AF: 0.0000131 AC: 2AN: 152212Hom.: 0 Cov.: 33 AF XY: 0.0000269 AC XY: 2AN XY: 74366
ClinVar
Submissions by phenotype
beta Thalassemia Pathogenic:2
Pathogenic, no assertion criteria provided | clinical testing | Natera, Inc. | Sep 16, 2017 | - - |
Pathogenic, criteria provided, single submitter | clinical testing | Women's Health and Genetics/Laboratory Corporation of America, LabCorp | Aug 26, 2016 | Variant summary: The HBB c.332T>C (p.Leu111Pro) variant causes a missense change involving a conserved nucleotide with 4/4 in silico tools (SNPs&GO not captured due to low reliability index) predicting a "damaging" outcome. The variant of interest was observed in the large, broad control population, ExAC, with an allele frequency of 1/121382, which does not exceed the estimated maximal expected allele frequency for a pathogenic HBB variant of 1/89. The variant of interest has been reported in multiple affected individuals in both homozygous and compound heterozygous states. In addition, a reputable database cites the variant as "pathogenic." Therefore, the variant of interest has been classified as Pathogenic. - |
not provided Pathogenic:2
Pathogenic, criteria provided, single submitter | clinical testing | Quest Diagnostics Nichols Institute San Juan Capistrano | May 22, 2023 | The HBB c.332T>C (p.Leu111Pro) pathogenic variant (also known as Hb Showa-Yakushiji) is reported in the published literature as a hyper unstable variant associated with beta thalassemia major and intermedia (PMIDs: 28670940 (2017), 27263053 (2016), 18495504 (2008), 15768552 (2005), 2634667 (1989), 2822177 (1987)). Analysis of this variant using bioinformatics tools for the prediction of the effect of amino acid changes on protein structure and function yielded predictions that this variant is damaging. Based on the available information, this variant is classified as pathogenic. - |
Pathogenic, criteria provided, single submitter | clinical testing | ARUP Laboratories, Molecular Genetics and Genomics, ARUP Laboratories | Mar 03, 2023 | The Hb Showa-Yakushiji variant (HBB: c.332T>C; p.Leu111Pro, also known as Leu110Pro when numbered from the mature protein, rs35256489, HbVar ID: 485) is reported to be a hyperunstable hemoglobin associated with beta(+) thalassemia (Colah 2008, Edison 2005, Kobayashi 1987, HbVar link). This variant is reported as pathogenic in ClinVar (Variation ID: 15352). It is only observed in one allele in the Genome Aggregation Database, indicating it is not a common polymorphism. The leucine at codon 111 is highly conserved, and computational analyses predict that this variant is deleterious (REVEL: 0.871). Based on available information, this variant is considered to be pathogenic. References: Link to HbVar database: https://globin.bx.psu.edu/hbvar/menu.html Colah R et al. Hb Showa Yakushiji (beta 110 (G12) Leu-->Pro) in 3 families from Western India: first report on homozygous Hb Showa Yakushiji. Blood Cells Mol Dis. 2008 Sep-Oct;41(2):166-8. PMID: 18495504. Edison ES et al. Hb Showa-Yakushiji (beta110(G12)Leu-->Pro) in four unrelated patients from west Bengal. Hemoglobin. 2005;29(1):19-25. PMID: 15768552. Kobayashi Y et al. A novel globin structural mutant, Showa-Yakushiji (beta 110 Leu-Pro) causing a beta-thalassemia phenotype. Blood. 1987 Nov;70(5):1688-91. PMID: 2822177. - |
Beta-Showa-Yakushiji thalassemia Pathogenic:1
Pathogenic, no assertion criteria provided | literature only | OMIM | Jan 01, 2005 | - - |
Hb SS disease Pathogenic:1
Pathogenic, criteria provided, single submitter | clinical testing | Baylor Genetics | - | - - |
Beta-plus-thalassemia Pathogenic:1
Pathogenic, no assertion criteria provided | literature only | OMIM | Jan 01, 2005 | - - |
HEMOGLOBIN SHOWA-YAKUSHIJI Other:1
other, no assertion criteria provided | literature only | OMIM | Dec 12, 2017 | - - |
Computational scores
Source:
Splicing
Find out detailed SpliceAI scores and Pangolin per-transcript scores at